Now available. Read our 2025 Impact Report
Avidity Biosciences, Inc. (Nasdaq: RNA), has announced new positive AOC 1001 data demonstrating improvement in multiple functional endpoints and favorable long-term safety and tolerability in people living with myotonic dystrophy […]
September is Fall Prevention Awareness Month and was the subject of our Wellness Hour. Falls are the second most common cause of injury leading to death. For a person with […]
Fulcrum Therapeutics has announced successful completion of patient enrollment in REACH Phase 3 trial The FSHD Society is thrilled to announce a significant milestone in the battle against FSHD. Fulcrum […]
Uniting the FSHD Community in Advancing Research by Nizar Saad, PhD, Columbus, Ohio On July 8th, our lab at Nationwide Children’s Hospital (NCH) in Columbus, Ohio, in collaboration with NCH, […]
by Helen Cave and the Women on Wellness group Dry eyes, also known as Ocular Surface Disease (OSD), is a common issue with many in the FSHD community. Symptoms are […]
English English 
العربية
Español de México
Français du Canada
简体中文
